The Latest

ACRO has partnered with TransCelerate BioPharma to develop a new acceptable ranges considerations tool to supp (…)

On this special episode of ACRO’s Good Clinical Podcast, 2025 ACRO Chair Jim Reilly (President, Development (…)

Today, ACRO announced four new data governance resource, co-developed with TransCelerate BioPharma. Created to assi (…)

This week, ACRO’s Good Clinical Podcast returns for a special episode! Lauren Garson (Senior Director, Clini (…)

ACRO is pleased to announce the seven clinical research sites that will receive grant funding as part of the ACRO D (…)

WASHINGTON, DC – Washington DC – ACRO today announced that its Board of Directors elected Jim Reilly, Executive Vice (…)

In 2024, ACRO’s RBQM Working Group conducted the fifth consecutive year of its annual risk-based quality management (R (…)

In ACRO’s latest paper published in DIA’s Therapeutic Innovation and Regulatory Science, “Risk-Based Quality Man (…)

WASHINGTON, DC – Today, ACRO’s RBQM Working Group has announced the publication of its latest RBM/RBQM paper, Risk-B (…)